Pharmaceutical composition for safe and effective treatment of knee and/or hip pain

A method for monitoring treatment of a subject having pain in the knee joint or the hip joint, the method comprising:

• administering a pharmaceutical composition comprising a dose of about 9 mg of an anti-NGF antibody that specifically binds to NGF or an antigen binding fragment thereof;
• monitoring a joint of the subject to determine whether the subject has developed an arthropathy;
• wherein if the subject has developed an arthropathy, administering a pharmaceutical composition comprising a dose of less than about 9 mg of the antibody or the antigen binding fragment thereof to the subject;
• or
• wherein if the subject has not developed an arthropathy, administering a pharmaceutical composition comprising a dose of about 9 mg of the antibody or the antigen binding fragment thereof to the subject.

A method of treating a subject having pain in the knee joint or the hip joint, comprising:

• diagnosing the patient as non-responsive to analgesic treatment or as suffering from a side-effect from analgesic treatment:
• and
• administering to the patient a therapeutically effective amount of an anti-nerve growth factor (NGF) antibody that binds specifically to NGF or an antigen binding fragment thereof;
• and
• whereby the pharmaceutical composition reduces pain in the knee joint or the hip joint of the subject.

A method of treating a subject having pain in the knee joint or the hip joint, comprising:

• diagnosing the patient as non-responsive to analgesic treatment or as suffering from a side-effect from analgesic treatment;
• and
• administering to the patient a pharmaceutical composition comprising 1.0 mg of an anti-nerve growth factor (NGF) antibody that binds specifically to NGF or an antigen binding fragment thereof;
• wherein the anti-NGF antibody or the antigen binding fragment thereof comprises a heavy chain variable region (HCVR)/light chain variable region (LCVR) amino acid sequence pair of SEQ ID NOs:
• 2/10;
• whereby the pharmaceutical composition reduces pain in the knee joint or the hip joint of the subject.

A method of reducing overall incidences of adverse events in a patient population treated with an anti-NGF antibody that binds specifically to NGF or an antigen binding fragment thereof, comprising:

• administering to the patient a pharmaceutical composition comprising 1.0 mg of an anti-nerve growth factor (NGF) antibody that binds specifically to NGF or an antigen binding fragment thereof;
• wherein the anti-NGF antibody or the antigen binding fragment thereof comprises a heavy chain variable region (HCVR)/light chain variable region (LCVR) amino acid sequence pair of SEQ ID NOs:
• 2/10;
• whereby incidences of adverse events in a patient population are reduced relative to patients treated with higher doses of NGF.

A method of treating a subject having pain in the knee joint or the hip joint, comprising:

• diagnosing the patient as non-responsive to analgesic treatment or as suffering from a side-effect from analgesic treatment;
• and
• administering to the patient a pharmaceutical composition comprising 1.0 mg of an anti-nerve growth factor (NGF) antibody that binds specifically to NGF or an antigen binding fragment thereof;
• whereby the pharmaceutical composition reduces pain in the knee joint or the hip joint of the subject and wherein the occurrence of one or more adverse events in the patient is reduced relative to patients treated with higher doses of the NGF antibody.

A method of reducing pain, or for improving physical function in a patient suffering from osteoarthritis, wherein the patient is non-responsive to analgesic treatment or is suffering from a side-effect from analgesic treatment, the method comprising:

• diagnosing the patient as non-responsive to analgesic treatment or as suffering from a side-effect from analgesic treatment;
• and
• administering to the patient a pharmaceutical composition comprising 1.0 mg of an anti-nerve growth factor (NGF) antibody that binds specifically to NGF or an antigen binding fragment thereof;
• whereby the pharmaceutical composition reduces pain, or improves physical function in the patient and wherein the occurrence of one or more adverse events in the patient is reduced relative to patients treated with higher doses of the NGF antibody.